Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

648
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
648
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

440
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
440
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

332
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
332
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

1.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

772
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
772
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

546
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
546

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Mild autonomic cortisol secretion: comorbidities and surgical treatment outcomes].

Medicina·2025
Same author

Challenges in the treatment of hypothyroidism: malabsorption and pseudo-malabsorption of levothyroxine.

Medicina·2025
Same author

Primary empty sella

Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina)·2025
Same author

Double pituitary adenoma associated with acromegaly and hyperprolactinemia: a case report.

Archives of endocrinology and metabolism·2025
Same author

[Sarcopenia: new cut-off value of handgrip in postmenopausal Argentine women].

Medicina·2024
Same author

Acromegaly and Cancer: An Update.

Archives of medical research·2023
Same journal

Detection of VIM-3 in oral squamous cell carcinomas: methodological limitations.

Medicina·2026
Same journal

The importance of specific antibodies in VIM-3 research: addressing a key methodological flaw.

Medicina·2026
Same journal

[From the right to be cared for to the duty to care: Legal bases for the implementation of palliative care in Argentina].

Medicina·2026
Same journal

[Surrogacy].

Medicina·2026
Same journal

[The misunderstandings in interpreting the "diagnostic superiority of Artificial Intelligence" and the explainable Artificial Intelligence].

Medicina·2026
Same journal

[Artificial intelligence in medicine: between algorithmic opacity and clinical responsibility].

Medicina·2026
See all related articles

Related Experiment Video

Updated: Nov 28, 2025

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

74.9K

Hyperprolactinemia associated with psychiatric disorders.

Leonardo F L Rizzo1,2, Daniela L Mana1, Héctor A Serra1,3

  • 1Dirección Médica, Química Montpellier SA, Argentina.

Medicina
|November 30, 2020
PubMed
Summary
This summary is machine-generated.

Hyperprolactinemia, often linked to psychiatric issues, can be caused by antipsychotic medications or arise during hyperprolactinemia treatment. This review offers diagnostic and management strategies for clinicians.

Keywords:
antipsychoticsdopamine agonistshyperprolactinemiaimpulse control disorders

More Related Videos

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

957
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.1K

Related Experiment Videos

Last Updated: Nov 28, 2025

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

74.9K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

957
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.1K

Area of Science:

  • Endocrinology
  • Psychiatry
  • Clinical Medicine

Background:

  • Hyperprolactinemia is frequently associated with psychiatric disorders.
  • Two primary scenarios link these conditions: antipsychotic-induced hyperprolactinemia and psychiatric issues from hyperprolactinemia treatment.
  • These associations are common yet often overlooked in psychiatric and endocrine practices.

Purpose of the Study:

  • To enhance awareness and understanding of hyperprolactinemia in psychiatric patients.
  • To provide practical diagnostic and treatment tools for managing hyperprolactinemia in psychiatric contexts.
  • To encourage collaborative management between psychiatrists and endocrinologists for this clinical entity.

Main Methods:

  • Literature review focusing on the interplay between hyperprolactinemia and psychiatric disorders.
  • Analysis of diagnostic criteria and treatment guidelines for hyperprolactinemia.
  • Discussion of clinical scenarios and management strategies.

Main Results:

  • Identified two main pathways linking hyperprolactinemia and psychiatric disorders.
  • Highlighted the underrecognition of these conditions in clinical practice.
  • Emphasized the need for specific diagnostic and therapeutic approaches.

Conclusions:

  • Effective management requires recognizing the dual scenarios of hyperprolactinemia and psychiatric disorders.
  • Integrated care involving psychiatrists and endocrinologists is crucial.
  • Implementing provided diagnostic and treatment tools can improve patient outcomes.